Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476540 | 0.84 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL11078629 | 0.83 | OPRL1 (0.51) | OPRM1OPRL1OPRK1HSD11B1MEN1 | |
| Hydrochloric Acid SCHEMBL1141265 | 0.82 | OPRM1 (0.58) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL4022665 | 0.81 | OPRM1 (0.44) | OPRM1OPRL1OPRK1HSD11B1MEN1 | |
| SCHEMBL517788 | 0.81 | OPRM1 (0.44) | OPRM1OPRL1OPRK1HSD11B1MEN1 | |
| SCHEMBL517752 | 0.81 | OPRL1 (0.69) | OPRM1OPRL1OPRK1MEN1CYP2C9 | |
| SCHEMBL16823730 | 0.80 | OPRL1 (0.50) | OPRM1OPRL1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL11098093 | 0.80 | OPRM1 (0.42) | OPRM1OPRL1OPRK1HSD11B1MEN1 | |
| SCHEMBL3404808 | 0.79 | OPRM1 (0.65) | OPRM1OPRL1OPRK1 | |
| SCHEMBL11099050 | 0.79 | OPRM1 (0.46) | OPRM1OPRL1OPRK1HSD11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | claimed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | claimed |
| EP-1406858-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | GRUENENTHAL GMBH (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7183436-B2 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20040236104-A1 | Substituted 4-aminocyclohexanols | GRUENENTHAL GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1406858-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003008370-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOLS | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4447454-A | Analgetic compounds, compositions and process of treatment | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4113866-A | ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236104-A1 | Substituted 4-aminocyclohexanols | CNR2, OPRK1, OPRL1 | OPRM1 7/4885OPRL1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.